BFC Planning’s Lineage Cell Therapeutics LCTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$258K Hold
270,170
– – 0.01% 845
2026
Q2
$354K Hold
270,170
– – 0.01% 735
2026
Q1
$427K Hold
270,170
– – 0.02% 621
2025
Q4
$451K Hold
270,170
– – 0.02% 580
2025
Q3
$457K Hold
270,170
– – 0.03% 408
2025
Q2
$245K Hold
270,170
– – 0.02% 563
2025
Q1
$122K Buy
270,170
+30,000
+12% +$17.6K 0.01% 790
2024
Q4
$121K Buy
240,170
+50,000
+26% +$36.7K 0.01% 788
2024
Q3
$172K Buy
+190,170
New +$176K 0.02% 660

Other funds holding LCTX

BFC Planning's LCTX Position: Q3 2026 in Review

BFC Planning held its Lineage Cell Therapeutics (LCTX) position steady in Q3 2026 at 270,170 shares worth $258K. The position accounts for 0.01% of the portfolio, ranked #845.

BFC Planning first reported a position in LCTX in Q3 2024 and has held it in 9 quarters since. The position peaked at $457K in Q3 2025. 110 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.

  • BFC Planning held 270,170 shares of Lineage Cell Therapeutics worth $258K as of Q3 2026.
  • BFC Planning left its Lineage Cell Therapeutics share count unchanged in Q3 2026.
  • Lineage Cell Therapeutics made up 0.01% of BFC Planning's portfolio in Q3 2026, its #845 holding.
  • BFC Planning first reported a position in Lineage Cell Therapeutics in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's Lineage Cell Therapeutics position peaked at $457K in Q3 2025.
  • 110 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.